{"filing":{"accession_number":"0001171843-26-005322","cik":"0001628808","ticker":"PROF","company_name":"Profound Medical Corp.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"f8k_080626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326005322/f8k_080626.htm"},"events":[{"id":25479,"run_id":23130,"accession_number":"0001171843-26-005322","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Profound Medical's Q2 2026 financial results for the quarter ended June 30, 2026. The press release reports total revenue of $2.5 million (up 12% YoY, or 153% excluding shipment timing), gross margin of 78%, operating expenses declining 16%, and net loss improving 39% to $9.5 million. The company also reiterates full-year 2026 revenue guidance of $25.0 million. The filing includes condensed consolidated balance sheets and is furnished as Exhibit 99.1 to Item 2.02, which is the standard Item for results of operations and financial condition.","company_name":"Profound Medical Corp.","ticker":"PROF","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26318,"accession_number":"0001171843-26-005322","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Profound Medical's Q2 2026 financial results for the quarter ended June 30, 2026. The press release reports total revenue of $2.5 million (up 12% YoY, or 153% excluding shipment timing), gross margin of 78%, operating expenses declining 16%, and net loss improving 39% to $9.5 million. The company also reiterates full-year 2026 revenue guidance of $25.0 million. The filing includes condensed consolidated balance sheets and is furnished as Exhibit 99.1 to Item 2.02, which is the standard Item for results of operations and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:48:09.496554+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26318,"accession_number":"0001171843-26-005322","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Profound Medical's Q2 2026 financial results for the quarter ended June 30, 2026. The press release reports total revenue of $2.5 million (up 12% YoY, or 153% excluding shipment timing), gross margin of 78%, operating expenses declining 16%, and net loss improving 39% to $9.5 million. The company also reiterates full-year 2026 revenue guidance of $25.0 million. The filing includes condensed consolidated balance sheets and is furnished as Exhibit 99.1 to Item 2.02, which is the standard Item for results of operations and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:48:09.496554+00:00","company_name":"Profound Medical Corp.","ticker":"PROF","filing_date":"2026-08-06"}]}